Psychologic dyspareunia

Summary

Psychologic dyspareunia (MONDO:0001196) is a disease. A subtype of psychosexual disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	psychologic dyspareunia
Mondo ID	MONDO:0001196
MeSH	D004414
DOID	DOID:11120
SNOMED CT	41021005
UMLS	C0154466
MedGen	509600
Is cancer (heuristic)	no

Also known as: dyspareunia, psychogenic

Disease family

This is a subtype of psychosexual disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › sexual disorder › psychosexual disorder › psychologic dyspareunia

Related subtypes (4): paraphilic disorder, psychologic vaginismus, hypoactive sexual desire disorder, orgasm disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Estradiol	Approved (phase 4)
Estrogens, Conjugated	Approved (phase 4)
Ospemifene	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.